The estimated Net Worth of Paul Giannasca is at least $0 dollars as of 11 September 2014. Paul Giannasca owns over 4,071 units of Genocea Biosciences Inc stock worth over $0 and over the last 11 years Paul sold GNCA stock worth over $0.
Paul has made over 4 trades of the Genocea Biosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Paul exercised 4,071 units of GNCA stock worth $8,223 on 11 September 2014.
The largest trade Paul's ever made was exercising 6,760 units of Genocea Biosciences Inc stock on 27 August 2014 worth over $19,334. On average, Paul trades about 2,811 units every 2 days since 2014. As of 11 September 2014 Paul still owns at least 4,071 units of Genocea Biosciences Inc stock.
You can see the complete history of Paul Giannasca stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE, MA, 02140.
Over the last 11 years, insiders at Genocea Biosciences Inc have traded over $9,875,933 worth of Genocea Biosciences Inc stock and bought 177,421,644 units worth $259,728,894 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Genocea Biosciences Inc executives and independent directors trade stock every 27 days with the average trade being worth of $0. The most recent stock trade was executed by Diantha Duvall on 2 June 2022, trading 1,355 units of GNCA stock currently worth $81.
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Genocea Biosciences Inc executives and other stock owners filed with the SEC include: